FDA to review removal of Eli Lilly weight loss drug from shortage list
The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ...
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...
Knockoff weight loss drug sellers are fighting back against Eli Lilly and the FDA
Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...
Eli Lilly widens obesity reach with $1.4B KeyBioscience deal
Eli Lilly (NYSE:LLY) has expanded its ongoing collaboration with Swiss biotech KeyBioscience in a bid to obtain global rights ...
Eli Lilly obesity drug shortage ends fueling lawsuit against FDA
A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...
STAT13h
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...
STAT1d
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
AG, Eli Lilly spar before the Michigan Supreme Court over insulin pricing investigation
The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...
Hoodline18h
Michigan Attorney General Fights to Revoke Decades-Old Rulings Shielding Pharma Giant Eli Lilly from Insulin Pricing Scrutiny
Michigan's Supreme Court reexamines rulings that may affect how the state's consumer protection laws apply to insulin pricing ...
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Eli Lilly & Co: Buy Rating Justified Despite Short-Term Sales Miss
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...